[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing
This article details an SEC Form 144 filing by MADRIGAL PHARMACEUTICALS, INC. (MDGL) submitted on May 22, 2026. The filing indicates a proposed sale of 5,682 shares of common stock with an aggregate market value of $2,918,218.38, acquired through exercised stock options. The sale will be executed via Morgan Stanley Smith Barney LLC on NASDAQ.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced the grant of equity inducement awards to 15 new non-executive employees on May 15, 2026. These awards, totaling 5,308 time-based restricted stock units, were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize their acceptance of employment. The units will vest in four equal annual installments, contingent upon continued employment.
Madrigal hires 15 staff, grants 5,308 stock units vesting over 4 years
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it granted 5,308 restricted stock units to 15 new non-executive employees on May 15, 2026. These inducement awards, approved under Nasdaq Listing Rule 5635(c)(4), vest in four equal annual installments and are contingent on continued employment. The company continues its pattern of stock-based hiring, following strong recent performance of its MASH drug, Rezdiffra.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced that it granted equity awards to 15 new non-executive employees on May 15, 2026, as inducement awards under its 2025 Inducement Plan. These awards, totaling 5,308 time-based restricted stock units, were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment. The company specializes in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with Rezdiffra being its key approved medication.
Madrigal to present Rezdiffra data at EASL Congress 2026
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it will present new data from its Rezdiffra development and real-world evidence programs at the European Association for the Study of the Liver Congress 2026. The presentations will cover lipid profile improvements, MASH cirrhosis risk scores, and the effectiveness of noninvasive biomarkers. This follows strong financial performance and positive analyst revisions for MDGL.
Madrigal to present Rezdiffra data at EASL Congress 2026 By Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it will present new data from its Rezdiffra development and real-world evidence programs at the EASL Congress 2026. This includes secondary analyses from its Phase 3 trials on lipid profiles and two-year data examining MASH cirrhosis patients, alongside early real-world evidence and biomarker studies. The company, which saw a 257% revenue surge and 93% gross profit margin, recently exceeded analyst expectations for Q1 2026 earnings, with its stock potentially undervalued according to InvestingPro.
Insider sale notice: MDGL (NASDAQ: MDGL) 844 shares via Morgan Stanley
Madrigal Pharmaceuticals (MDGL) submitted a Rule 144 notice to sell 844 shares of Common Stock. This transaction follows a Restricted Stock Unit grant that vested on May 15, 2026, with Morgan Stanley Smith Barney LLC listed as the broker. The filing date for this procedural disclosure was May 18, 2026.
Madrigal (NASDAQ: MDGL) CMO has 844 shares sold automatically for tax withholding
Madrigal Pharmaceuticals (NASDAQ: MDGL) Chief Medical Officer David Soergel had 844 shares of common stock automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. The sale, valued at $435,420, occurred at an average price of $515.90 per share. Following this non-discretionary transaction, Soergel directly holds 11,075 shares.
What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders
Madrigal Pharmaceuticals (MDGL) reported wider Q1 2026 net losses of US$94.39 million, up from US$73.24 million a year earlier, despite strong year-on-year revenue growth from its drug Rezdiffra. The company's investment narrative hinges on Rezdiffra becoming a foundational MASH therapy, but faces challenges from rising R&D and SG&A costs, and potential financing needs. Analysts have varied forecasts for the company, highlighting the uncertainty surrounding its future financial performance and the balance between early revenue traction and increasing expenses.
What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders
Madrigal Pharmaceuticals reported wider Q1 2026 net losses of US$94.39 million, up from US$73.24 million a year earlier, despite strong year-on-year revenue growth from its MASH drug Rezdiffra. The company's investment narrative centers on Rezdiffra becoming a foundational MASH therapy, but this is balanced against rising costs, competitive pressures, and potential financing needs. Analysts have varying revenue and earnings forecasts for Madrigal, highlighting the uncertainty around its future financial performance and stock valuation.
Madrigal Pharmaceuticals Issues Equity Awards to 47 New Hires
Madrigal Pharmaceuticals has granted equity inducement awards to 47 new non-executive employees as it expands operations following the commercial launch of its MASH treatment, Rezdiffra. The awards include stock options, time-based restricted stock units, and performance-based restricted stock units. These grants are part of employment compensation packages as the company builds its commercial and operational capacity for Rezdiffra, the first approved therapy for MASH with moderate to advanced fibrosis.
Paulson & Co. (MDGL) holds 1.39M shares, representing 6.1% of Madrigal
Paulson & Co. filed an amended Schedule 13G/A, reporting beneficial ownership of 1,392,188 shares of Madrigal Pharmaceuticals, Inc. Common Stock, which constitutes 6.1% of the class. The filing indicates that Paulson exercises sole voting and dispositive power over these shares through its advisory funds, but disclaims beneficial ownership, meaning the economic interest lies with the funds themselves. This disclosure is based on 22,939,969 shares of Madrigal outstanding as of February 12, 2026.
Madrigal Rezdiffra Sales More Than Double in First Quarter
Madrigal Pharmaceuticals reported a significant increase in first-quarter Rezdiffra sales, which more than doubled to $311.3 million, driven by strong physician adoption and growing patient demand for its MASH treatment. Despite this revenue growth, the company posted a net loss of $94.4 million due to increased research and development, and selling, general and administrative expenses as it expanded its pipeline and marketing efforts. Madrigal also announced new licensing and siRNA development deals to strengthen its focus on liver disease therapies.
Janus Henderson (MDGL) discloses 2,018,647-share stake, 8.8% ownership
Janus Henderson Group plc has disclosed a beneficial ownership of 2,018,647 shares in Madrigal Pharmaceuticals (MDGL), representing an 8.8% stake. This ownership is managed across various Asset Managers with shared voting and dispositive power for client's Managed Portfolios. The filing clarifies that Janus Henderson does not have rights to dividends or sale proceeds from these shares, as they belong to the Managed Portfolios.
Number of shareholders of Madrigal Pharmaceuticals, Inc. – GETTEX:YDO1
This article provides details on the number of shareholders for Madrigal Pharmaceuticals, Inc. (GETTEX:YDO1). It focuses on presenting shareholder data, possibly including period values and changes, within the TradingView platform context. The content is primarily a data placeholder and navigational artifact for the financial instrument.
(MDGL) Risk Channels and Responsive Allocation
This article analyzes Madrigal Pharmaceuticals Inc. (MDGL), highlighting weak near-term sentiment but long-term strength. It details an exceptional short setup and outlines three AI-generated trading strategies: Long Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss points. The analysis also provides multi-timeframe signal strengths and support/resistance levels.
Truist raises Madrigal Pharmaceuticals stock price target on MASH survey
Truist Securities has increased its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) to $709 from $640, maintaining a Buy rating. This adjustment follows survey data indicating physician preference for Madrigal's MASH drug, Rezdiffra, and an increased forecast for US peak MASH patients treated with the drug. The company recently reported strong first-quarter 2026 earnings, surpassing analyst expectations for both EPS and revenue.
Truist raises Madrigal Pharmaceuticals stock price target on MASH survey By Investing.com
Truist Securities has increased its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) to $709 from $640, maintaining a Buy rating, following a survey indicating strong physician preference for Madrigal's MASH treatment, Rezdiffra. The firm also raised its forecast for US peak MASH patients treated with Rezdiffra in 2036 to 193,000, up from 158,000, expecting this to drive significant revenue. Madrigal recently reported Q1 2026 earnings that exceeded analyst expectations for both EPS and revenue.
Madrigal Pharmaceuticals expands its MASH treatment pipeline
Madrigal Pharmaceuticals has acquired worldwide rights to ARO-PNPLA3 from Arrowhead Pharmaceuticals, an experimental genetic treatment for MASH, particularly targeting Hispanic patients with a specific PNPLA3 mutation. This expands Madrigal's MASH pipeline, complementing their approved drug Rezdiffra. The deal involves an upfront payment of $25 million and potential milestone payments up to $975 million, plus royalties.
Madrigal Pharmaceuticals Q1 2026 Deep Dive: EPS Beats by 20.9%, Revenue Up 127%
Madrigal Pharmaceuticals reported a strong Q1 2026, with EPS beating expectations by 20.9% and revenue surging 127% year-over-year to $311.3 million. The company's sole commercial product, Rezdiffra, continues its market penetration, leading to a 7.4% stock rally. Despite a modest sequential revenue decline, improved net margin and strong gross margins indicate increasing operational leverage.
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals, based in West Conshohocken, has secured a potential $1 billion licensing deal with Arrowhead Pharmaceuticals. This agreement grants Madrigal exclusive global rights to develop ARO-PNPLA3, an experimental therapy targeting a genetic mutation linked to MASH liver disease. The deal aims to expand Madrigal's treatment pipeline following the significant success of its FDA-approved drug Rezdiffra, the first treatment for MASH, which generated nearly $1 billion in sales in the past year.
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals
Madrigal Pharmaceuticals (MDGL) is under analysis following the blockbuster success of its drug Rezdiffra and new MASH pipeline deals. Despite recent stock volatility, analysts peg its fair value at $671.07, suggesting it is undervalued, supported by ambitious revenue expansion and profit margin growth. However, future performance depends on Rezdiffra success and competitive pressures in the MASH market.
How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors
Madrigal Pharmaceuticals reported a net loss of US$94.39 million in Q1 2026, despite Rezdiffra generating US$311.3 million in revenue. The company is broadening its MASH pipeline, including licensing Arrowhead’s ARO‑PNPLA3, shifting its investment narrative from a single-drug focus to a broader, combination-oriented franchise in liver disease. This strategy aims to establish Rezdiffra as a backbone therapy, complemented by genetic and metabolic add-ons, while managing substantial losses and cash burn.
Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative
Madrigal Pharmaceuticals (MDGL) reported a Q1 2026 loss of US$94.4 million despite significant revenue growth to US$311.3 million. This performance challenges the bullish narrative of a swift margin turnaround, as trailing losses remain heavy at US$309 million, and losses have widened over the past five years. While analysts predict future profitability and substantial revenue growth fueled by Rezdiffra, the current financials and ongoing losses present execution risks for investors.
47 new Madrigal hires get stock awards; options priced at $513.72
Madrigal Pharmaceuticals announced it granted inducement equity awards to 47 new non-executive employees on May 1, 2026, under its 2025 Inducement Plan. These awards include 5,312 stock options, 17,589 time-based Restricted Stock Units (RSUs), and 1,839 performance-based RSUs, with options priced at $513.72. The awards are designed to incentivize new hires and support the company's ongoing growth and product commercialization efforts.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced the grant of equity inducement awards to 47 new non-executive employees on May 1, 2026. These awards, totaling 5,312 stock options, 17,589 time-based restricted stock units, and 1,839 performance-based restricted stock units, were approved under Nasdaq Listing Rule 5635(c)(4) to attract talent. The options have an exercise price of $513.72 per share, and all awards have specific vesting schedules contingent on continued employment.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript
Madrigal Pharmaceuticals reported strong Q1 2026 earnings, with Rezdiffra achieving over $1.1 billion in net sales over the last 12 months, indicating blockbuster status despite the MASH market still being in its early stages. The company is strategically expanding its pipeline with assets like ARO-PNPLA3 to complement Rezdiffra and address specific patient subgroups, aiming for long-term leadership in the rapidly growing MASH treatment landscape. Madrigal expects continued strong growth for Rezdiffra, steadily increasing its patient base and progressing towards profitability beyond 2026, while also advancing its F4C outcomes trial for Rezdiffra.
Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative
Madrigal Pharmaceuticals reported a Q1 2026 net income loss of US$94.4 million and a basic EPS loss of US$4.13, despite total revenue reaching US$311.3 million. The company's trailing twelve-month losses stand at US$309 million on US$1.1 billion in revenue, raising questions about the bullish narrative of a swift margin turnaround, as losses continue to widen. Analysts anticipate significant future earnings growth and margin improvement, but current financial results present a mixed picture for investors.
Rezdiffra powers Madrigal Pharmaceuticals (NASDAQ: MDGL) to 127% Q1 revenue growth
Madrigal Pharmaceuticals reported a significant 127% year-over-year revenue growth in Q1 2026, reaching $311.3 million, primarily driven by its MASH drug, Rezdiffra, which has achieved blockbuster status with over 42,250 patients. Despite increased operating expenses, including one-time business development costs and non-cash stock-based compensation, the company ended the quarter with a strong cash position of $817.9 million. Madrigal also strengthened its pipeline by licensing a clinical-stage siRNA asset targeting the PNPLA3 gene and advancing other MASH therapeutic programs.
Madrigal Pharmaceuticals Releases Q1 2026 Financial Results
Madrigal Pharmaceuticals (MDGL) announced Q1 2026 financial results, reporting a narrower-than-expected loss of $3.25 per share, surpassing analyst estimates by 20.9%. The company generated $311.3 million in revenue, driven by strong sales of its MASH treatment, Rezdiffra, which saw a 127% increase year-over-year. Despite a net loss of $94.4 million due to continued investments, Wall Street maintains a positive outlook, with a consensus of 15 buy ratings.
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3
Madrigal Pharmaceuticals and Bayer have announced significant deals to expand their pipelines. Madrigal entered an exclusive global licensing agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage siRNA therapy targeting metabolic dysfunction-associated steatohepatitis (MASH), in a deal potentially worth over $1 billion. Concurrently, Bayer agreed to fully acquire Perfuse Therapeutics for up to $2.45 billion ($300 million upfront), aiming to strengthen its ophthalmology franchise with PER-001 for glaucoma and diabetic retinopathy.
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat
Madrigal Pharmaceuticals reported a significant earnings beat for Q1 2026, with an EPS of -$3.25 against a forecasted -$4.19 and revenue of $311.3 million exceeding expectations. The company highlighted 127% year-over-year net sales growth, reaching blockbuster status with over $1.1 billion in trailing twelve-month net sales, primarily driven by strong performance of Rezdiffra in the rapidly expanding MASH market. Madrigal also outlined its R&D strategy focused on advancing combination therapies with Rezdiffra as a foundational treatment and maintaining a robust pipeline, including a recently in-licensed siRNA asset targeting the PNPLA3 gene.
Madrigal Pharmaceuticals (NASDAQ: MDGL) grows Rezdiffra revenue but remains loss-making
Madrigal Pharmaceuticals reported a significant increase in Rezdiffra revenue for Q1 2026, reaching $311.3 million, up from $137.3 million a year earlier, driven by U.S. and initial European launches. Despite this growth, total operating expenses rose to $404.1 million, resulting in a net loss of $94.4 million, or $3.25 per share, indicating that the franchise is not yet self-funding. The company is actively expanding its MASH-focused pipeline through various licensing deals for new therapeutic candidates.
Madrigal: Q1 Earnings Snapshot
Madrigal Pharmaceuticals Inc. (MDGL) reported a first-quarter loss of $94.4 million, or $3.25 per share, surpassing Wall Street expectations. The biopharmaceutical company also recorded revenue of $311.3 million, exceeding analyst forecasts. These results indicate a stronger-than-anticipated financial performance for the quarter.
Madrigal Pharmaceuticals, Inc. announced that its drug interaction study for Ervogastat/Resmetirom is progressing steadily and is expected to officially launch in the fourth quarter of 2026.
Madrigal Pharmaceuticals, Inc. has announced that its drug interaction study for Ervogastat/Resmetirom is progressing well and is anticipated to launch officially in the fourth quarter of 2026. This study aims to provide crucial data on the potential interactions of the combined therapy in clinical applications. The information is expected to support future development of the drug.
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals announced strong first-quarter 2026 financial results, with Rezdiffra net sales reaching $311.3 million, a 127% increase year-over-year. The company reported over 42,250 patients on Rezdiffra and expanded its pipeline with a clinical-stage siRNA asset targeting the PNPLA3 gene for MASH. Madrigal also maintains a strong cash position of $817.9 million and will present new data at the upcoming EASL Congress.
Madrigal: Q1 Earnings Snapshot
Madrigal Pharmaceuticals Inc. (MDGL) reported a first-quarter loss of $94.4 million, or $3.25 per share, which exceeded Wall Street's expectations. The biopharmaceutical company also posted revenues of $311.3 million, surpassing analyst forecasts. These results were generated using data from Zacks Investment Research.
Madrigal: Q1 Earnings Snapshot
Madrigal Pharmaceuticals Inc. (MDGL) reported a first-quarter loss of $94.4 million, or $3.25 per share, which was better than Wall Street's expectations. The biopharmaceutical company also posted revenue of $311.3 million, surpassing analyst forecasts. These results highlight the company's financial performance for the period.
Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH
Madrigal Pharmaceuticals, the company behind the first FDA-approved MASH drug, Rezdiffra, has expanded its combination therapy strategy by licensing ARO-PNPLA3 from Arrowhead Pharmaceuticals. This siRNA therapy targets a genetic mutation linked to MASH progression and has shown promising results in Phase 1 trials. This deal, Madrigal's second involving siRNA therapies and fourth overall in the past year, aims to address the multi-factorial nature of MASH and potentially enhance Rezdiffra's long-term efficacy and market durability.
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead
Madrigal Pharmaceuticals has licensed ARO-PNPLA3, an RNA interference candidate targeting a genetic mutation in MASH patients, from Arrowhead Pharmaceuticals. The deal includes $25 million upfront and up to $1 billion in total payments. ARO-PNPLA3 complements Madrigal's existing MASH strategies, including its FDA-approved drug Rezdiffra, by targeting a different genetic driver and has shown promising Phase 1 results in reducing liver fat.
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals.
Arrowhead Pharmaceuticals has entered into a significant collaboration agreement with Madrigal Pharmaceuticals, centered on Arrowhead's proprietary technology for treating non-alcoholic steatohepatitis (NASH). Madrigal will provide an upfront payment of $25 million, with potential future payments reaching $975 million based on development milestones. The deal could bring Arrowhead total revenues of up to $1 billion as therapies advance through development, registration, and commercialization.
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals has licensed its clinical-stage RNA interference therapeutic, ARO-PNPLA3, to Madrigal Pharmaceuticals. ARO-PNPLA3 targets the PNPLA3 gene to treat metabolic dysfunction-associated steatohepatitis (MASH), particularly in patients with the I148M mutation, which is common among Hispanic patients. Early Phase 1 clinical data showed significant reductions in liver fat and a good safety profile, with Madrigal making a $25 million upfront payment and Arrowhead eligible for up to $975 million in milestones and tiered royalties.
After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug
Arrowhead Pharmaceuticals has licensed its clinical-stage RNA interference therapeutic, ARO-PNPLA3, to Madrigal Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The agreement follows compelling Phase 1 data showing a 46% reduction in liver fat in MASH patients with a specific genetic mutation. Madrigal will make an upfront payment of $25 million, with Arrowhead eligible for up to $975 million in milestone payments and tiered royalties on commercial sales.
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Madrigal Pharmaceuticals has acquired an exclusive global license for ARO-PNPLA3, a clinical-stage siRNA asset from Arrowhead Pharmaceuticals, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This precision medicine targets a genetic driver of MASH, particularly prevalent in Hispanic populations, and demonstrated significant liver fat reduction in Phase 1 trials. The asset will complement Madrigal's existing MASH treatment, Rezdiffra, and planning for combination studies is underway.
Is It Time To Reassess Madrigal Pharmaceuticals (MDGL) After Its Strong Five Year Share Price Gain
Madrigal Pharmaceuticals (MDGL) has shown mixed share price performance recently, with a significant 293.9% gain over five years but declines year-to-date. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 71.1%, with an intrinsic value of $1,776.49 per share against a current price of $513.72. The Price-to-Sales (P/S) ratio of 12.30x also indicates undervaluation compared to its estimated Fair Ratio of 14.78x.
Vanguard Group Inc. Trims Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Vanguard Group Inc. has slightly reduced its position in Madrigal Pharmaceuticals, Inc. by 0.2%, selling 3,160 shares but still holding a significant stake valued at over $1.05 billion. This comes as Madrigal Pharmaceuticals reported a quarterly EPS miss despite strong revenue growth year-over-year. Institutional ownership in the company remains high at approximately 98.5%, though insiders have recently been net sellers.
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $536
BofA Securities has reiterated a Hold rating on Madrigal Pharmaceuticals (MDGL.US) and increased its target price to $536. This update suggests a continued cautious but not negative outlook on the company's stock, reflecting BofA's revised valuation.
Madrigal Pharmaceuticals (NasdaqGS:MDGL) Stock Forecast & Analyst Predictions
Madrigal Pharmaceuticals (MDGL) is projected to experience significant growth, with earnings forecast to increase by 56.3% and revenue by 28.9% annually. Analysts anticipate the company will become profitable within the next three years, with a high return on equity of 54.6% in the same period. Recent analyst updates show mixed sentiment with price target adjustments reflecting factors like gross-to-net considerations and Rezdiffra's commercial potential.
Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial
Madrigal Pharmaceuticals (MDGL) is expanding the potential use of its drug resmetirom by initiating a Phase 2 trial for post-transplant MASH patients. This randomized, double-blind, placebo-controlled study will evaluate resmetirom in patients with moderate to advanced fibrosis who have undergone a liver transplant, addressing a significant unmet medical need. Positive data from this trial could enhance Madrigal's valuation, as few competitors are targeting this complex niche.
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Moves And Rezdiffra Expectations
Madrigal Pharmaceuticals (MDGL) has seen mixed share price performance recently but has delivered substantial long-term gains. Analysts assess its fair value at $671.07, deeming it undervalued, primarily due to the potential of its drug Rezdiffra for MASH. However, a Discounted Cash Flow model suggests an even higher fair value of $1,778.26 per share, indicating significant undervaluation, while acknowledging risks such as competition and reimbursement pressures for Rezdiffra.
